Caspofungin Therapy Aids ALL Patients with Invasive Fungal Disease

Caspofungin Therapy Aids ALL Patients with Invasive Fungal Disease

caspofunginExciting news was shared in the January 2015 issue of Mycoses, with clinical data revealing that the use of Caspofungin to treat invasive fungal disease in leukemia patients was both positive and responsive. Adult patients who were diagnosed with acute lymphoblastic leukemia attained relief from their suspected fungal disease after the clinical use of Caspofungin. As an effectual member of the echinocandin drug class Caspofungin is often used in patients who have not responded to prior antifungal treatments. Caspofungin has, however, proved to be widely effective for treating an array of serious fungal infections, particularly in immunocompromised patients such as the patient population aforementioned. The administration of Caspofungin is done intravenously, with a typical dosage being dispensed slowly over a one hour period. Side effects can sometimes include nausea, diarrhea, and headache and skin flushing.

The risk of invasive and life-threatening fungal disease is specifically common in patients with acute lymphoblastic leukemia (ALL). This patient group will be at a greater risk for this virulent fungal disease typically after either a hematopoietic stem cell transplantation or cytotoxic chemotherapy. Data gleaned from the study shared in Mycoses showed that when patients with ALL who received Caspofungin empirically attained treatment that was deemed therapeutically effective. Nine medical centers in Germany participated in the ALL/Caspofungin data analysis, with information being collected between 2006 and 2012. Therapy duration of at least 8 days of treatment with Caspofungin in these patients with suspected invasive fungal disease proved that 95 percent of patients attained efficacy, including those patients who were considered critically ill.

LGM Pharma can assist clients as a supplier/distributor of the API Caspofungin, CAS #162808-62-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service